SCHEMBL4586476

SCHEMBL4586476

COc1ccc2cc(C=O)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
TSHR P16473 1/20 0.46
FDPS P14324 1/20 0.44
AOX1 Q06278 1/20 0.42
TRIM24 O15164 1/20 0.42
HPGD P15428 1/20 0.42
ALDH5A1 P51649 1/20 0.42
ABAT P80404 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
CYP2A6 P11509 3/20 0.41
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
ERN1 O75460 1/20 0.39
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081464 1.00 ALDH1A1 (0.46) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL2233220 0.85 ALDH1A1 (0.50) ALDH1A1TSHRTRIM24TRIM33CYP2A6
SCHEMBL26634026 0.79 KDM4E (0.54) ALDH1A1TSHRHPGDTDP1HDAC3
SCHEMBL27138895 0.78 SRC (0.39) CYP2A6
SCHEMBL11830895 0.77 MTNR1A (0.45) ALDH1A1HPGDHDAC3HDAC4HDAC1
SCHEMBL1223679 0.77 TRPM5 (0.45) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL4586080 0.77 ALDH1A1 (0.43) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL31428581 0.77 CYP1A2 (0.57) ALDH1A1HPGDCYP2A6MAPTCYP1A2
SCHEMBL4587005 0.77 CYP1A2 (0.57) ALDH1A1HPGDCYP2A6MAPTCYP1A2
SCHEMBL29935754 0.77 CYP1A2 (0.57) ALDH1A1HPGDCYP2A6MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113999232-B MAT2A inhibitors 南京正大天晴制药有限公司 2025-01-07 CN disclosed
CN-107406414-B (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer 基因泰克公司 2022-04-19 CN disclosed
CN-113999232-A MAT2A inhibitors 南京正大天晴制药有限公司 2022-02-01 CN disclosed
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US disclosed
EP-1879563-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-07-16 EP disclosed
EP-1879563-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-01-23 EP disclosed
WO-2006132739-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214455-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 ALDH1A1 4089/4885TSHR 4599/4885FDPS 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.